Antioxidant efcts of Abexol in middle-aged and older subjects
Phase 3
- Conditions
- Oxidative strees in middle-aged and older subjectOxidative StressAging
- Registration Number
- RPCEC00000401
- Lead Sponsor
- ational Centre for Scientific Research (CNIC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Subjects who provided written informed consent for participating in the trial
Exclusion Criteria
Patients with:
1) Diagnosed thyroid
2) Hepatic and/or renal diseases active
3) Diagnosed cancer
4) Uncontrolled diabetes (fasting glucose a head 7)
5) Arterial hypertension (diastolic pressure a head 100 mmHg)
6) Values of blood indicators: ALT or AST a head 55 UI, creatinine a head 130 umol/L
7) Has suffered myocadial infarction, unstable angina, stroke, ATI, major surgery, within six months prior the study
8) Consuming antioxidant supplements or vitamins within the last 4 weeks prior the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Malondiialdehyde (MDA) (nmmol/MDA/mL). Measurement time: At baseline and 12 weeks (Significant decrease of values at the end of treatment respect baseline values and values of the placebo group)<br>2. Total Hydroperoxides (nmol/mg protein). Measurement time: At baseline and 12 weeks (Significant decrease of values at the end of treatment respect baseline values and values of the placebo group)
- Secondary Outcome Measures
Name Time Method Total antioxidant status (mL whole blood). Measurement time: At baseline ans 12 weeks (Singnifican increase of values at the end of treatment respect baseline values and values of the placebo group)